stockportfolio.pro
Prothena Corporation plc (PRTA)
Healthcare · Biotechnology · NasdaqGS
Prothena Corporation plc revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.05M | $27.52M | $955,000 | $814,000 | $853,000 | $200.58M | $53.91M | $91.37M | $135.16M | $9.68M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-160.11M | $-153.24M | $-155.65M | $-77.68M | $-111.14M | $66.97M | $-116.95M | $-147.03M | $-122.31M | $-244.09M |
| Net margin | -15176.1% | -556.8% | -16297.9% | -9542.6% | -13029.8% | 33.4% | -217.0% | -160.9% | -90.5% | -2520.6% |
Source: Prothena Corporation plc SEC filings (10-K). 15 years of history available in the interactive view.
Explore 15 years of Prothena Corporation plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PRTA in your portfolio →
Prothena Corporation plc financial history by metric
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Prothena Corporation plc — frequently asked questions
What is Prothena Corporation plc's revenue?
Prothena Corporation plc (PRTA) reported revenue of $9.68M for fiscal year 2025, down 92.8% from the prior year, according to its SEC filings.
Is Prothena Corporation plc profitable?
No — PRTA reported a net loss of $-244.09M in fiscal 2025.
What is PRTA's P/E ratio?
Prothena Corporation plc trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Prothena Corporation plc growing?
PRTA's revenue grew at roughly 62.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Prothena Corporation plc have?
As of fiscal year 2025, PRTA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Prothena Corporation plc's market cap?
Prothena Corporation plc (PRTA) has a market capitalization of about $436.63M, based on the latest data in our nightly-refreshed cache.
When does Prothena Corporation plc's fiscal year end?
PRTA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Prothena Corporation plc's official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.